神经变性的蛋白质组学。

Mark D Johnson, Li-Rong Yu, Thomas P Conrads, Yoshito Kinoshita, Takuma Uo, Joshua K McBee, Timothy D Veenstra, Richard S Morrison
{"title":"神经变性的蛋白质组学。","authors":"Mark D Johnson,&nbsp;Li-Rong Yu,&nbsp;Thomas P Conrads,&nbsp;Yoshito Kinoshita,&nbsp;Takuma Uo,&nbsp;Joshua K McBee,&nbsp;Timothy D Veenstra,&nbsp;Richard S Morrison","doi":"10.2165/00129785-200505040-00006","DOIUrl":null,"url":null,"abstract":"<p><p>The continuing improvement and refinement of proteomic and bioinformatic tools has made it possible to obtain increasing amounts of structural and functional information about proteins on a global scale. The emerging field of neuroproteomics promises to provide powerful strategies for further characterizing neuronal dysfunction and cell loss associated with neurodegenerative diseases. Neuroproteomic studies have thus far revealed relatively comprehensive quantitative changes and post-translational modifications (mostly oxidative damage) of high abundance proteins, confirming deficits in energy production, protein degradation, antioxidant protein function, and cytoskeletal regulation associated with neurodegenerative diseases such as Alzheimer and Parkinson disease. The identification of changes in low-abundance proteins and characterization of their functions based on protein-protein interactions still await further development of proteomic methodologies and more dedicated application of these technologies by neuroscientists. Once accomplished, however, the resulting information will certainly provide a truly comprehensive view of neurodegeneration-associated changes in protein expression, facilitating the identification of novel biomarkers for the early detection of neurodegenerative diseases and new targets for therapeutic intervention.</p>","PeriodicalId":72171,"journal":{"name":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00129785-200505040-00006","citationCount":"30","resultStr":"{\"title\":\"The proteomics of neurodegeneration.\",\"authors\":\"Mark D Johnson,&nbsp;Li-Rong Yu,&nbsp;Thomas P Conrads,&nbsp;Yoshito Kinoshita,&nbsp;Takuma Uo,&nbsp;Joshua K McBee,&nbsp;Timothy D Veenstra,&nbsp;Richard S Morrison\",\"doi\":\"10.2165/00129785-200505040-00006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The continuing improvement and refinement of proteomic and bioinformatic tools has made it possible to obtain increasing amounts of structural and functional information about proteins on a global scale. The emerging field of neuroproteomics promises to provide powerful strategies for further characterizing neuronal dysfunction and cell loss associated with neurodegenerative diseases. Neuroproteomic studies have thus far revealed relatively comprehensive quantitative changes and post-translational modifications (mostly oxidative damage) of high abundance proteins, confirming deficits in energy production, protein degradation, antioxidant protein function, and cytoskeletal regulation associated with neurodegenerative diseases such as Alzheimer and Parkinson disease. The identification of changes in low-abundance proteins and characterization of their functions based on protein-protein interactions still await further development of proteomic methodologies and more dedicated application of these technologies by neuroscientists. Once accomplished, however, the resulting information will certainly provide a truly comprehensive view of neurodegeneration-associated changes in protein expression, facilitating the identification of novel biomarkers for the early detection of neurodegenerative diseases and new targets for therapeutic intervention.</p>\",\"PeriodicalId\":72171,\"journal\":{\"name\":\"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2165/00129785-200505040-00006\",\"citationCount\":\"30\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2165/00129785-200505040-00006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00129785-200505040-00006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 30

摘要

蛋白质组学和生物信息学工具的不断改进和完善使得在全球范围内获得越来越多的蛋白质结构和功能信息成为可能。神经蛋白质组学这一新兴领域有望为进一步表征与神经退行性疾病相关的神经元功能障碍和细胞损失提供强有力的策略。迄今为止,神经蛋白质组学研究已经揭示了相对全面的高丰度蛋白质的定量变化和翻译后修饰(主要是氧化损伤),证实了与阿尔茨海默病和帕金森病等神经退行性疾病相关的能量产生、蛋白质降解、抗氧化蛋白功能和细胞骨架调节的缺陷。低丰度蛋白变化的鉴定及其基于蛋白-蛋白相互作用的功能表征仍有待于蛋白质组学方法的进一步发展和神经科学家对这些技术的更专门的应用。然而,一旦完成,所得到的信息肯定会提供一个真正全面的关于神经退行性疾病相关蛋白质表达变化的观点,促进识别神经退行性疾病早期检测的新生物标志物和治疗干预的新靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The proteomics of neurodegeneration.

The continuing improvement and refinement of proteomic and bioinformatic tools has made it possible to obtain increasing amounts of structural and functional information about proteins on a global scale. The emerging field of neuroproteomics promises to provide powerful strategies for further characterizing neuronal dysfunction and cell loss associated with neurodegenerative diseases. Neuroproteomic studies have thus far revealed relatively comprehensive quantitative changes and post-translational modifications (mostly oxidative damage) of high abundance proteins, confirming deficits in energy production, protein degradation, antioxidant protein function, and cytoskeletal regulation associated with neurodegenerative diseases such as Alzheimer and Parkinson disease. The identification of changes in low-abundance proteins and characterization of their functions based on protein-protein interactions still await further development of proteomic methodologies and more dedicated application of these technologies by neuroscientists. Once accomplished, however, the resulting information will certainly provide a truly comprehensive view of neurodegeneration-associated changes in protein expression, facilitating the identification of novel biomarkers for the early detection of neurodegenerative diseases and new targets for therapeutic intervention.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Towards molecular medicine: a case for a biological periodic table. Genetic testing in Crohn disease: utility in individualizing patient management. Identifying DNA methylation biomarkers of cancer drug response. The Autism Genome Project: goals and strategies. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1